General Electric Co
Change company Symbol lookup
Select an option...
GE General Electric Co
LH Laboratory Corporation of America Holdings
ET Energy Transfer LP
BG Bunge Ltd
MSB Mesabi Trust
TRC Tejon Ranch Co
RMO Romeo Power Inc
RHI Robert Half International Inc
SITC Site Centers Corp
DHIL Diamond Hill Investment Group Inc
Go

Industrials : Industrial Conglomerates | Large Cap Value
Company profile

General Electric Company is an industrial company. The Company operates through its industrial segments, Power, Renewable Energy, Aviation and Healthcare, and its financial services segment, Capital. Its segments include Power, which serves power generation, industrial, government and other customers with products and services related to energy production; Renewable Energy, which provides solutions for renewable energy; Aviation, which includes commercial and military aircraft engines, and integrated digital components, electric power and mechanical aircraft systems; Healthcare, which provides healthcare technologies in medical imaging, digital solutions, patient monitoring and diagnostics, and drug discovery, and Capital, which is a financial services division. Its products include commercial and military aircraft engines and systems; healthcare systems and pharmaceutical diagnostics; wind and other renewable energy generation equipment; nuclear and other power generation equipment.

Closing Price
$64.46
Day's Change
-0.01 (-0.02%)
Bid
--
Ask
--
B/A Size
--
Day's High
65.06
Day's Low
64.19
Volume
(Below Average)
Volume:
6,657,732

10-day average volume:
7,473,533
6,657,732

Pfizer confirms to acquire Global Blood Therapeutics for $5.4 billion in deal that gives it access to sickle-cell disease treatment

6:56 am ET August 8, 2022 (MarketWatch)
Print

Pfizer Inc. (PFE) has agreed to buy Global Blood Therapeutics Inc. (GBT) in a deal valued at $5.4 billion, the companies said Monday, confirming a report by the Wall Street Journal. Pfizer will pay $68.50 a share in cash for Global Blood Therapeutics, which has one of few approved treatments for sickle-cell disease, a painful inherited blood disorder that most affects people of African, Middle Eastern and South Asian descent. The acquisition "complements and further enhances Pfizer's more than 30-year heritage in rare hematology and reinforces the company's commitment to SCD by bringing expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical needs in this underserved community," Pfizer said in a statement. The news sent Global Blood Therapeutics shares up 4.3% premarket. Pfizer will finance the deal using cash on hand.

-Ciara Linnane

	

(END) Dow Jones Newswires

August 08, 2022 06:56 ET (10:56 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.